Genomtec SA stock analysis
Genomtec SA (4VI) Stock Price & Analysis
4VI Stock Chart & Stats
- Day’s Range
- EUR 0.49 - EUR 0.56
- 52-Week Range
- EUR 0.49 - EUR 1.50
- Previous Close
- EUR 0.49
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.29M
- Enterprise Value
- EUR 63.76M
- Total Cash (Recent Filing)
- EUR 14.24M
- Total Debt (Recent Filing)
- EUR 1.55M
- Price to Earnings (P/E)
- ―
- Beta
- -0.42
- Next Earnings
- Nov 27, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
4VI FAQ
What was Genomtec SA’s price range in the past 12 months?
What is Genomtec SA’s market cap?
When is Genomtec SA’s upcoming earnings report date?
How were Genomtec SA’s earnings last quarter?
Is Genomtec SA overvalued?
Does Genomtec SA pay dividends?
What is Genomtec SA’s EPS estimate?
How many shares outstanding does Genomtec SA have?
What happened to Genomtec SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genomtec SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Genomtec SA
Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Miron Tokarski
- Employees
- 32
- Website
- www.genomtec.com
- Address
- Bierutowska Street 57-59, Wroclaw, DS, 51-317, PL
Genomtec SA (4VI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 9 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 6 | 0 | 6 |

